MA28359A1 - Antagonistes du recepteur a l'hydroisoindoline tachykinine - Google Patents

Antagonistes du recepteur a l'hydroisoindoline tachykinine

Info

Publication number
MA28359A1
MA28359A1 MA29265A MA29265A MA28359A1 MA 28359 A1 MA28359 A1 MA 28359A1 MA 29265 A MA29265 A MA 29265A MA 29265 A MA29265 A MA 29265A MA 28359 A1 MA28359 A1 MA 28359A1
Authority
MA
Morocco
Prior art keywords
antagonists
tachykinin receptor
hydroisoindoline
hydroisoindoline tachykinin
receptor
Prior art date
Application number
MA29265A
Other languages
English (en)
Inventor
Jaime Lynn Bunda
Robert J Devita
Jinlong Jiang
Sander G Mills
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA28359A1 publication Critical patent/MA28359A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA29265A 2004-01-27 2006-08-11 Antagonistes du recepteur a l'hydroisoindoline tachykinine MA28359A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53991304P 2004-01-27 2004-01-27
US56122704P 2004-04-09 2004-04-09

Publications (1)

Publication Number Publication Date
MA28359A1 true MA28359A1 (fr) 2006-12-01

Family

ID=34830494

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29265A MA28359A1 (fr) 2004-01-27 2006-08-11 Antagonistes du recepteur a l'hydroisoindoline tachykinine

Country Status (30)

Country Link
US (3) US7645790B2 (fr)
EP (1) EP1711465B1 (fr)
JP (1) JP3987100B2 (fr)
KR (1) KR20060127927A (fr)
AR (1) AR047439A1 (fr)
AT (1) ATE382034T1 (fr)
AU (1) AU2005207934B2 (fr)
BR (1) BRPI0507050A (fr)
CA (1) CA2554550C (fr)
CO (1) CO5700771A2 (fr)
CR (1) CR8522A (fr)
CY (1) CY1107167T1 (fr)
DE (1) DE602005004011T2 (fr)
DK (1) DK1711465T3 (fr)
EA (1) EA010598B1 (fr)
EC (1) ECSP066716A (fr)
ES (1) ES2297687T3 (fr)
GE (1) GEP20094691B (fr)
HR (1) HRP20080100T3 (fr)
IL (1) IL176879A0 (fr)
MA (1) MA28359A1 (fr)
NI (1) NI200600164A (fr)
NO (1) NO339041B1 (fr)
NZ (1) NZ548415A (fr)
PE (1) PE20050687A1 (fr)
PL (1) PL1711465T3 (fr)
PT (1) PT1711465E (fr)
TW (1) TWI341198B (fr)
UA (1) UA84192C2 (fr)
WO (1) WO2005073191A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI341198B (en) 2004-01-27 2011-05-01 Merck Sharp & Dohme Hydroisoindoline tachykinin receptor antagonists
US7652058B2 (en) 2004-12-14 2010-01-26 Merck Sharp & Dohme Corp. Octahydropyrano[3,4-C]pyrrole tachykinin receptor antagonists
CA2611550A1 (fr) * 2005-06-27 2007-01-04 Merck & Co., Inc. Antagonistes des recepteurs de tachykinine hydro-iso-indolique
JP2009500452A (ja) 2005-07-11 2009-01-08 メルク エンド カムパニー インコーポレーテッド ヒドロイソインドリンタキキニン受容体アンタゴニストの製造方法
WO2007044296A2 (fr) * 2005-10-04 2007-04-19 Merck & Co., Inc. Polytherapie destinee au traitement de la pollakiurie, de la miction imperieuse et de l'incontinence urinaire
WO2007075528A2 (fr) * 2005-12-22 2007-07-05 Merck & Co., Inc. Antagonistes de recepteur d’octahydropyrano[3,4-c]pyrrole-tachykinine
US20090042854A1 (en) * 2006-01-24 2009-02-12 Jianming Bao Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists
JP2010502703A (ja) * 2006-09-06 2010-01-28 メルク エンド カムパニー インコーポレーテッド 置換アミドの経口投与のための液体及び半固体の医薬製剤
EP2089019A4 (fr) * 2006-11-02 2011-05-04 Merck Sharp & Dohme Polymorphes d'un antagoniste des récepteurs de tachykinine hydro-iso-indolique
EP2141992A1 (fr) * 2007-03-29 2010-01-13 Merck & Co., Inc. Polythérapie pour le traitement de troubles urinaires du bas appareil
AU2008236639B2 (en) * 2007-04-10 2014-07-03 Merck Sharp & Dohme Corp. Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists
CA2796877A1 (fr) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Nouveaux agonistes du recepteur beta 3 adrenergique
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
WO2013004766A1 (fr) 2011-07-04 2013-01-10 Ferrari Giulio Antagonistes des récepteurs nk-1 pour traiter une néovascularisation cornéenne
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
CA2915474A1 (fr) * 2013-06-24 2014-12-31 Tigercat Pharma, Inc. Utilisation de serlopitant, antagoniste du recepteur nk -1, dans le traitement du prurit
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
AU2018290889B2 (en) 2017-06-30 2024-06-27 Alto Neuroscience, Inc. NK-1 antagonist compositions and methods for use in treating depression
RU2020131446A (ru) 2018-02-26 2022-03-28 Оспедале Сан Раффаэле С.Р.Л. Антагонисты nk-1 для применения в лечении глазной боли
EP4117673A1 (fr) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Traitement d'une déficience en cellules souches
BR112022018876A2 (pt) 2020-04-03 2022-11-22 Nerre Therapeutics Ltd Antagonista de receptor de nk-1 para tratar uma doença selecionada a partir de sepse, choque séptico, síndrome de desconforto respiratório agudo (ards) ou síndrome de disfunção múltipla dos órgãos
MX2022014901A (es) 2020-06-02 2023-01-18 Nerre Therapeutics Ltd Antagonistas del receptor de neuroquinina (nk)-1 para su uso en el tratamiento de condiciones de fibrosis pulmonar promovidas por lesion mecanica a los pulmones.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650142A (en) * 1995-09-27 1997-07-22 Church & Dwight Co., Inc. Bicarbonate-containing deodorant cosmetic stick compositions
WO1997014671A1 (fr) 1995-10-18 1997-04-24 Merck & Co., Inc. Antagonistes des recepteurs de la cyclopentyle-tachykinine
JP2007507504A (ja) 2003-09-30 2007-03-29 メルク　エンド　カムパニー　インコーポレーテッド フェニルピロリジンエーテル系タキキニン受容体拮抗薬
TWI341198B (en) 2004-01-27 2011-05-01 Merck Sharp & Dohme Hydroisoindoline tachykinin receptor antagonists

Also Published As

Publication number Publication date
NZ548415A (en) 2009-11-27
TWI341198B (en) 2011-05-01
AU2005207934A1 (en) 2005-08-11
NI200600164A (es) 2007-05-29
AU2005207934B2 (en) 2010-11-25
EP1711465A1 (fr) 2006-10-18
EA010598B1 (ru) 2008-10-30
WO2005073191A1 (fr) 2005-08-11
CO5700771A2 (es) 2006-11-30
US7345083B2 (en) 2008-03-18
ECSP066716A (es) 2006-10-31
JP2007519728A (ja) 2007-07-19
AR047439A1 (es) 2006-01-18
NO20063810L (no) 2006-10-26
PE20050687A1 (es) 2005-09-27
US7645790B2 (en) 2010-01-12
DE602005004011T2 (de) 2008-12-11
PT1711465E (pt) 2008-02-25
CY1107167T1 (el) 2012-10-24
CA2554550A1 (fr) 2005-08-11
US20050165083A1 (en) 2005-07-28
NO339041B1 (no) 2016-11-07
PL1711465T3 (pl) 2008-05-30
EA200601378A1 (ru) 2007-02-27
EP1711465B1 (fr) 2007-12-26
GEP20094691B (en) 2009-05-25
ATE382034T1 (de) 2008-01-15
US20080280966A1 (en) 2008-11-13
US7217731B2 (en) 2007-05-15
BRPI0507050A (pt) 2007-06-12
ES2297687T3 (es) 2008-05-01
CR8522A (es) 2007-06-06
HK1100937A1 (zh) 2007-10-05
UA84192C2 (en) 2008-09-25
KR20060127927A (ko) 2006-12-13
DE602005004011D1 (de) 2008-02-07
IL176879A0 (en) 2006-10-31
HRP20080100T3 (en) 2008-04-30
US20070161695A1 (en) 2007-07-12
TW200534850A (en) 2005-11-01
JP3987100B2 (ja) 2007-10-03
DK1711465T3 (da) 2008-03-31
CA2554550C (fr) 2011-05-03

Similar Documents

Publication Publication Date Title
EP1725238A4 (fr) Antagonistes du recepteur muscarinique a l'acetylcholine m 3
NO20051871D0 (no) Opioid reseptorantagonister
EP2049110A4 (fr) Diazépans pontés antagonistes du récepteur de l'oréxine
DK1638969T3 (da) CGRP-receptorantagonister
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
MA29034B1 (fr) Posologie d'un agoniste du recepteur s1p
DE602005004011D1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
EP1765805A4 (fr) Antagonistes des recepteurs du cgrp
EP1641781A4 (fr) Antagonistes du recepteur cgrp de benzodiazepine
EP1791843A4 (fr) Antagonistes de recepteurs cgrp d'anilide spirolactame monocyclique
EP1740177A4 (fr) Antagonistes des recepteurs muscariniques de l'acetylcholine
MA29080B1 (fr) Derives de la quinuclidine et leur utilisation en tant qu'antagonistes du recepteur m3 muscarinique
EP1444251A4 (fr) Peptides cycliques comme antagonistes du recepteur couple a la proteine g
EP1871752A4 (fr) Antagonistes du récepteur de l' orexine de type amidopropoxyphényle
EP1814550A4 (fr) Antagonistes du recepteur 1 de n-sulfonylpiperidine cannabinoide
EP1827421A4 (fr) Modulateurs du recepteur de l'oestrogene
IS8522A (is) Ný M3 múskarínasetýlkólínviðtakamótlyf
IS8515A (is) Ný M3 múskarínasetýlkólínviðtakamótlyf
EP1799672A4 (fr) Antagonistes du recepteur de cgrp
MA28363A1 (fr) Antagonistes des recepteurs muscariniques de l'acetylcholine
EP1819342A4 (fr) Antagonistes de récepteurs de tachykinine de type quinoline
EP1951042A4 (fr) Antagonistes du recepteur cgrp du spirolactam
EP2076285A4 (fr) Antagonistes d'anticorps du récepteur 1 de l'interleukine-13
EP1819677A4 (fr) Antagonistes du recepteur de tachykinine de 8-phenyl-5,6,7,8-hydroquinoline
EP1951228A4 (fr) Antagonistes du recepteur cgrp biclyclique de spirohydantoine